Intriguingly, given the availability of existing NR agonists in the market and the observation that some NR agonists can upregulate the expression of hOCT1, an independent predictor of therapeutic response, combining NR agonists and TKIs could shed new lights on the development of novel therapeutic regimens for CML patients. Here, SLC22A1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.